Mastering Gout Management Guidelines for SCE Rheumatology Success

Gout is one of the most common forms of inflammatory arthritis worldwide, and it remains a high-yield topic for the SCE Rheumatology examination. A solid understanding of current diagnostic criteria, treatment protocols, and long-term management strategies is essential for success in this exam and in clinical practice.

Understanding Gout: Pathophysiology Basics

Gout results from the deposition of monosodium urate (MSU) crystals in joints and tissues due to persistent hyperuricemia. The condition typically presents in four phases: asymptomatic hyperuricemia, acute gouty arthritis, intercritical gout, and chronic tophaceous gout. Understanding this progression is crucial for both exam success and patient management.

Key risk factors include:

• Male gender (men are 3-4 times more likely than women)

• Age (risk increases after 40 in men, after 60 in women)

• Diet rich in purines (red meat, seafood, alcohol)

• Obesity and metabolic syndrome

• Certain medications (diuretics, low-dose aspirin)

• Family history of gout

• Chronic kidney disease

Diagnostic Criteria and Investigation

The 2015 ACR/EULAR classification criteria are widely accepted and frequently tested. Points are awarded based on:

Clinical Features:

• Pattern of joint involvement (first MTP joint = ankle/foot = knee = other joints)

• Characteristics of attack (monoarthritis rapid onset, pain severe, swelling, erythema)

• Time to maximal pain (<24 hours)

• Resolution within 14 days

• Evidence of tophi

Laboratory:

• Serum uric acid level (controversial during acute attack)

• Synovial fluid analysis showing negatively birefringent, needle-shaped crystals

Imaging:

• Ultrasound showing "double contour sign"

• DECT (Dual-Energy CT) for detecting urate deposits

Key Point for Exam: During an acute attack, serum uric acid may be normal—never exclude gout based on a normal uric acid level during an acute flare.

Acute Gout Management Guidelines

First-Line Treatment Options:

1. NSAIDs (First-line unless contraindicated)

• Naproxen 750mg initially, then 250-500mg 8-12 hourly

• Indomethacin 50mg three times daily

• Celecoxib 400-800mg loading, then 200-400mg

• Continue until 1-2 days after symptoms resolve (usually 7-14 days)

2. Colchicine

• Traditional dosing: 1.2mg initially, then 0.6mg after 1 hour, then 0.6mg 12 hourly

• Low-dose regimen now preferred: 0.6mg once or twice daily

• Reduce dose in renal impairment

• Monitor for bone marrow suppression

3. Oral Corticosteroids

• Prednisolone 30-35mg daily for 5-7 days

• Equivalent dosing if switching

• Often preferred in patients with contraindications to NSAIDs/colchicine

4. Intra-articular Corticosteroids

• Highly effective for monoarticular involvement

• Particularly useful in patients with multiple comorbidities

Important Considerations:

• Avoid starting urate-lowering therapy during an acute attack

• If patient is already on urate-lowering therapy, continue it during the attack

• Prophylaxis with colchicine 0.6mg daily should be considered when starting urate-lowering therapy

Long-Term Management: Urate-Lowering Therapy (ULT)

Indications for Starting ULT:

• Recurrent flares (≥2 per year)

• Tophi

• Chronic kidney disease stage 2 or worse

• Joint damage visible on X-ray

• Serum uric acid >8 mg/dL

• Urolithiasis

Urate-Lowering Therapy Options:

1. Xanthine Oxidase Inhibitors:

• Allopurinol: First-line

  • Start at 50-100mg daily

  • Titrate every 2-4 weeks to target uric acid <6 mg/dL (or <5 mg/dL with tophi)

  • Maximum dose 900mg daily

  • Risk of hypersensitivity syndrome (HLA-B*5801 testing recommended in high-risk populations)

• Febuxostat: Second-line or if allopurinol intolerant

  • Start at 40mg daily, increase to 80mg if needed

  • More potent than allopurinol

  • Cardiovascular safety concerns—use with caution

2. Uricosurics:

• Probenecid: Second-line

  • Start at 250mg twice daily, titrate to 1-2g daily

  • Monitor uric acid target

  • Ineffective in renal impairment (eGFR <30)

  • Increased risk of urolithiasis

3. Pegloticase:

• Reserved for severe, refractory gout

• Intravenous infusion every 2 weeks

• Reserved for patients with tophi who fail other therapies

Target Uric Acid Goals:

• General population: <6 mg/dL (360 μmol/L)

• Patients with tophi: <5 mg/dL (300 μmol/L)

Lifestyle Modifications

While medication is cornerstone, lifestyle changes are important:

• Limit alcohol intake (especially beer and spirits)

• Reduce purine-rich foods (red meat, organ meats, seafood)

• Limit fructose-sweetened beverages

• Maintain adequate hydration (2-3 liters daily)

• Lose weight if overweight/obese

• Consider vitamin C supplementation (500mg daily may lower uric acid)

• Cherry extract may help reduce attacks

SCE Exam Pearls

1. Acute attack management: NSAIDs, colchicine, or steroids—never start allopurinol during an acute flare

2. Prophylaxis: Continue colchicine 0.6mg daily for 6 months when starting ULT

3. Target uric acid: <6 mg/dL generally, <5 mg/dL with tophi

4. Allopurinol dosing: Start low, titrate up gradually

5. Aspiration: Golden standard for diagnosis—demonstrates MSU crystals

6. First MTP joint: Classic presentation (podagra)

7. Renal function: Affects choice of uricosuric vs xanthine oxidase inhibitor

Common Exam Scenarios

Scenario 1: First Presentation

A 45-year-old male presents with severe pain, swelling, and erythema of his right first toe. He reports the pain started suddenly at 3 AM and was maximal within 6 hours. What is your approach?

Answer: Suspect acute gout. Aspirate joint for crystals (gold standard). Treat with NSAID/colchicine/steroids. Give lifestyle advice. Only start ULT if recurrent episodes or other indications.

Scenario 2: Patient on Allopurinol with Flare

A patient has been on allopurinol for 3 weeks and presents with an acute flare. What do you do?

Answer: Continue allopurinol (don't stop). Treat acute flare with appropriate therapy. Ensure patient is on colchicine prophylaxis.

Scenario 3: Refractory Gout

A patient with tophaceous gout continues to have flares despite being on maximum allopurinol and having uric acid <6 mg/dL. What next?

Answer: Consider febuxostat, probenecid, or combination therapy. If still uncontrolled, consider pegloticase.

Conclusion

Gout management is a fundamental topic in rheumatology and appears frequently in the SCE examination. A thorough understanding of acute management, indications for urate-lowering therapy, treatment targets, and exam pearls will serve you well both in the exam and in clinical practice. Remember: treat the acute attack appropriately, then address hyperuricemia in a staged manner with clear targets.

Focus on the stepwise approach: diagnosis confirmation, acute treatment, lifestyle modifications, and finally urate-lowering therapy with clear targets. This systematic approach will help you manage gout patients effectively and excel in your SCE Rheumatology examination.